Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Transformed Non-Hodgkin LymphomaRecurrent Transformed Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 30
- Registration Number
- NCT02628405
- Locations
- 🇺🇸
Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States
🇺🇸Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02592876
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02544425
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 22
- Registration Number
- NCT02471911
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 8
- Registration Number
- NCT02441309
- Locations
- 🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇳🇱Department of Clinical Oncology, Leiden University Medical Center, Leiden, Postzone K1-P, Netherlands
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 117
- Registration Number
- NCT02432274
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇫🇷Centre Oscar Lambret Lille, Lille, Rhone, France
🇫🇷CHU de Toulouse - Hopital des Enfants, Toulouse, France
NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB
- Conditions
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 534
- Registration Number
- NCT02422563
First Line TIP in Poor Prognosis TGCTs.
- Conditions
- Interventions
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- National Cancer Institute, Slovakia
- Target Recruit Count
- 19
- Registration Number
- NCT02414685
- Locations
- 🇸🇰
National Cancer Institute, Bratislava, Slovakia
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Western Regional Medical Center
- Registration Number
- NCT02408042
- Locations
- 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.